Genome-based predictors for HCC outcomes: A matter of tumor and/or stroma  by Wang, Xin Wei & Thorgeirsson, Snorri S.
596 Letters to the Editor / Journal of Hepatology 51 (2009) 593–600veillance and treatment were performed at each site) [6].
In fact, Lee’s survival signature [5], developed in Chinese
patients whose outcome is assumedly driven by ‘‘early”
recurrence, had no obvious association with survival in
patient series collected from the US, Europe, and Japan,
in which ‘‘late” recurrence was the major driver of out-
come, although the signature was clearly reproduced in
all of these series [2].
There is no doubt tumor-derived molecular
information is important in terms of therapeutic target
discovery, and it is ideal to conﬁrm that it is associated
with patient outcome, i.e., ‘‘early” recurrence, at least in
the particular patient series in the study to rationalize
targeting the gene or pathway. However, the unstable
association could be a signiﬁcant limitation to utilize
the tumor-derived molecular information as a prognos-
tic marker, which should stably work across diverse pa-
tient populations across the world.
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Genome-based predictors for HCC outcomes: A matter of tumor
and/or stroma
To the Editor:
We appreciate the response by Yujin Hoshida [1]
regarding our interpretation [2] of his failure to iden-
tify tumor-associated survival genes when using the
informative gene panel approach described in his re-
cent study [3]. Hoshida argues that the informative
gene panel contains many genes reported to be
silenced in human tumors and thus insists that the
lack of tumor-derived survival genes in his recent
study is not due to the methodology used. Hoshida
concludes that the reason they are unable to identify
tumor-derived survival associated genes is due to the
type of recurrence they are studying. A majority of
cases in their cohorts have a late-recurrence, rather
than early-recurrence commonly found with cases
from most Asian cohorts. It is commonly believed
that late-recurrence is largely contributed by the devel-
opment of additional new tumor lesions due to high
carcinogenic activities in an at-risk liver while early-
recurrence is mainly attributed to metastatic disease.
His conclusion implies that no measurable molecular
change in the original HCC can be used to predict
the development of a new HCC, i.e., de novo HCC,
rather the ability to develop new HCC is only dictated
by the liver microenvironment. This is an interesting
idea but should be interpreted cautiously. We believe
such a conclusion is premature based on the current
body of evidence. Numerous tumor suppressor genes
and oncogenes have been identiﬁed to be responsible
for the development of HCC. For example, p53,
APC, beta-catenin and Myc, along with the transcripts
of their downstream targets, are frequently disregulat-
ed in HCC. The transcripts associated with these
molecular signaling pathways should be readily detect-
able in tumor cells. It is conceivable that some of
these transcripts could be predictive of the carcino-
genic activity common to HCC. While the informative
gene panel may contain many tumor suppressor genes,
many other important genes apparently are not in-
cluded. Because of the availability of the whole-gen-
ome DASL platform, such an uncertainty can now
be formally addressed. The mechanism for HCC
recurrence is currently unclear. Both early- and late-
recurrences can be independently attributed to meta-
Letters to the Editor / Journal of Hepatology 51 (2009) 593–600 597static and de novo HCC. Our preliminary experiments
suggest that a tumor-derived gene signature could be
found to be predictive for HCC late-recurrence (Bud-
hu et al., unpublished data). This is analogous to the
recent ﬁndings that both tumor and non-tumor-de-
rived gene signatures can predict HCC early-recur-
rence in multiple cohorts [4–9]. Thus, the jury is still
out and further studies are needed.
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A new French paradox: HBV vaccination
To the Editor:
In his recent article, DS Chen indicated that the hep-
atitis B vaccine was an innovation from France [1].
When listing the challenges that need to be overcome
to extend hepatitis B mass vaccination he could have ci-
ted France again. The percentage of one-year-olds
immunized with three doses of Hepatitis B in France
was 29% in 2006 (vs. 86% in Germany, a comparable
country), lower than most of the very poor countries
in the world [2].
Recently, a paper by a French team published in a
major journal concluded that ‘‘Engerix B vaccine ap-
pears to increase the risk of CNS inﬂammatory demye-
lination in childhood” [3]. A pre-publication release
campaign worsened the message in the newspapers.
This research was conducted with public funding
from several major national bodies. Evaluation could
have helped avoiding: (a) subgroup analyses without
a priori deﬁnition on the basis of known mechanisms
or in response to previous ﬁndings; (b) absence of
declaration of the number of analyses performed;
(c) lack of adjustment for multiple testing with tests
for heterogeneity [4]. These pitfalls are easy to
remember: Sleight showed, in a subgroup analysis
of patients from the ISIS- 2 trial, that aspirin therapy
was signiﬁcantly beneﬁcial for all patients except
those born under the astrological signs of Gemini
or Libra [5]!
Guidelines were generated to improve quality of epi-
demiological studies (eg ‘STrengthening the Reporting
of OBservational studies in Epidemiology’ (STROBE)
[6]. Funding agencies, reviewers and journals editors
must have actively endorsed these guidelines.
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